Compugen (CGEN) KOL event summary

Introduction and agenda

• Event covered COM701 in ovarian cancer and the continued evolution of Unigen; no new targets were disclosed.

• Interim MAIA-ovarian PFS analysis expected by Q1 2027.

KOL background and credentials

• Dr. Oladapo Yeku, MAIA-ovarian lead investigator at Harvard and Massachusetts General Hospital, discussed ovarian cancer treatment and COM701’s maintenance rationale.

Market insights and analysis

• Platinum sensitivity is defined by a platinum-free interval over six months; patients have more treatment options and longer survival than in platinum-resistant disease, though most eventually become resistant.

• Bevacizumab is a maintenance option, but contraindications, prior use, side effects, or patient preference can lead to observation instead.

• ADC maintenance trials are ongoing; efficacy results remain early, and added adverse effects and use of topoisomerase-1 payloads are concerns.

• Second-line PARP inhibitor maintenance use was withdrawn by the FDA after toxicity and overall-survival concerns.